Related Experiment Video
Updated: May 27, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient
Abdullah Katgi1, Pinar Ataca, Selda Kahraman
1Department of Hematology, Dokuz Eylul University, Izmir, Turkey. drakatgi@gmail.com
Acquired hemophilia is a rare, life-threatening coagulopathy in adults caused by the development of autoantibodies against factor VIII. Bypass agents such as recombinant factor VIIa (rFVIIa) are usually preferred for bleeding control; however, thromboembolic complications may occur. We report here a case that presented with extensive cutaneous and mucosal bleedings due to factor VIII inhibitors and was treated successfully with rFVIIa and steroid therapy, but was complicated with a life-threatening thromboembolic attack during follow-up.
Acquired hemophilia is a rare, life-threatening coagulopathy in adults caused by the development of autoantibodies against factor VIII. Bypass agents such as recombinant factor VIIa (rFVIIa) are usually preferred for bleeding control; however, thromboembolic complications may occur. We report here a case that presented with extensive cutaneous and mucosal bleedings due to factor VIII inhibitors and was treated successfully with rFVIIa and steroid therapy, but was complicated with a life-threatening thromboembolic attack during follow-up.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Hemorrhagic Stroke ll: Pathophysiology
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemorrhagic Stroke l: Introduction
Ischemic Stroke l: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

